rAbDesFlow: a novel workflow for computational recombinant antibody design for healthcare engineering

被引:0
|
作者
Krishnan, Sowmya Ramaswamy [1 ]
Sharma, Divya [1 ]
Nazeer, Yasin [1 ]
Bose, Mayilvahanan [2 ]
Rajkumar, Thangarajan [3 ,4 ,5 ]
Jayaraman, Guhan [1 ]
Madaboosi, Narayanan [1 ]
Gromiha, M. Michael [1 ,6 ,7 ]
机构
[1] Indian Inst Technol Madras, Bhupat & Jyoti Mehta Sch Biosci, Dept Biotechnol, Chennai 600036, India
[2] Canc Inst WIA, Dept Mol Oncol, Chennai 600020, India
[3] Indian Inst Technol Madras, Dept Appl Mech & Biomed Engn, Chennai 600036, India
[4] MedGenome, Bengaluru 560099, Karnataka, India
[5] Amrita Inst Med Sci, Dept Nanosci & Mol Med, Kochi 682041, Kerala, India
[6] Tokyo Inst Technol, Sch Comp, Int Res Frontiers Initiat, Yokohama 2268501, Japan
[7] Natl Univ Singapore NUS, Sch Comp, Singapore 119077, Singapore
关键词
rAbDesFlow; recombinant antibody engineering; computational workflow; CA-125; ovarian cancer; MONOCLONAL-ANTIBODY; PREDICTION; SERVER; AFFINITY; THERAPY; EPITOPE; CELLS;
D O I
10.1093/abt/tbae018
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Recombinant antibodies (rAbs) have emerged as a promising solution to tackle antigen specificity, enhancement of immunogenic potential and versatile functionalization to treat human diseases. The development of single chain variable fragments has helped accelerate treatment in cancers and viral infections, due to their favorable pharmacokinetics and human compatibility. However, designing rAbs is traditionally viewed as a genetic engineering problem, with phage display and cell free systems playing a major role in sequence selection for gene synthesis. The process of antibody engineering involves complex and time-consuming laboratory techniques, which demand substantial resources and expertise. The success rate of obtaining desired antibody candidates through experimental approaches can be modest, necessitating iterative cycles of selection and optimization. With ongoing advancements in technology, in silico design of diverse antibody libraries, screening and identification of potential candidates for in vitro validation can be accelerated. To meet this need, we have developed rAbDesFlow, a unified computational workflow for recombinant antibody engineering with open-source programs and tools for ease of implementation. The workflow encompasses five computational modules to perform antigen selection, antibody library generation, antigen and antibody structure modeling, antigen-antibody interaction modeling, structure analysis, and consensus ranking of potential antibody sequences for synthesis and experimental validation. The proposed workflow has been demonstrated through design of rAbs for the ovarian cancer antigen Mucin-16 (CA-125). This approach can serve as a blueprint for designing similar engineered molecules targeting other biomarkers, allowing for a simplified adaptation to different cancer types or disease-specific antigens. Statement of Significance: A computational workflow, rAbDesFlow, was developed for template-based humanized recombinant antibody design. The workflow utilizes open-sourced databases and tools with existing antibody sequences as templates. This approach can serve as a blueprint for designing similar engineered molecules targeting other biomarkers, allowing for a straightforward and simplified adaptation.
引用
收藏
页码:256 / 265
页数:10
相关论文
共 50 条
  • [21] Computational Design of a Novel VLP-Based Vaccine for Hepatitis B Virus
    Mobini, Saeed
    Chizari, Milad
    Mafakher, Ladan
    Rismani, Elmira
    Rismani, Elham
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [22] Emerging themes in the computational design of novel enzymes and protein-protein interfaces
    Khare, Sagar D.
    Fleishman, Sarel J.
    FEBS LETTERS, 2013, 587 (08) : 1147 - 1154
  • [23] Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen
    Hutchinson, Mark
    Ruffolo, Jeffrey A.
    Haskins, Nantaporn
    Iannotti, Michael
    Vozza, Giuliana
    Pham, Tony
    Mehzabeen, Nurjahan
    Shandilya, Harini
    Rickert, Keith
    Croasdale-Wood, Rebecca
    Damschroder, Melissa
    Fu, Ying
    Dippel, Andrew
    Gray, Jeffrey J.
    Kaplan, Gilad
    MABS, 2024, 16 (01)
  • [24] Structure-based computational design of antibody mimetics: challenges and perspectives
    Chaves, Elton J. F.
    Coelho, Danilo F.
    Cruz, Carlos H. B.
    Moreira, Emerson G.
    Simoes, Julio C. M.
    Nascimento-Filho, Manasses J.
    Lins, Roberto D.
    FEBS OPEN BIO, 2025, 15 (02): : 223 - 235
  • [25] Computational engineering the binding affinity of Adalimumab monoclonal antibody for designing potential biosimilar candidate
    Khan, Md Abdullah-Al-Kamran
    Turjya, Rafeed Rahman
    Islam, Abul Bashar Mir Md Khademul
    JOURNAL OF MOLECULAR GRAPHICS & MODELLING, 2021, 102 (102):
  • [26] Computational Design and Biological Depiction of Novel Naproxen Derivative
    Shah, Kamal
    Mujwar, Somdutt
    Krishna, Gaurav
    Gupta, Jeetendra K.
    ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2020, 18 (07) : 308 - 317
  • [27] Computational design of novel protein-protein interactions - An overview on methodological approaches and applications
    Marchand, Anthony
    Van Hall-Beauvais, Alexandra K.
    Correia, Bruno E.
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 2022, 74
  • [28] Unlocking the potential of enzyme engineering via rational computational design strategies
    Zhou, Lei
    Tao, Chunmeng
    Shen, Xiaolin
    Sun, Xinxiao
    Wang, Jia
    Yuan, Qipeng
    BIOTECHNOLOGY ADVANCES, 2024, 73
  • [29] A Novel Antibody Engineering Strategy for Making Monovalent Bispecific Heterodimeric IgG Antibodies by Electrostatic Steering Mechanism
    Liu, Zhi
    Leng, Esther C.
    Gunasekaran, Kannan
    Pentony, Martin
    Shen, Min
    Howard, Monique
    Stoops, Janelle
    Manchulenko, Kathy
    Razinkov, Vladimir
    Liu, Hua
    Fanslow, William
    Hu, Zhonghua
    Sun, Nancy
    Hasegawa, Haruki
    Clark, Rutilio
    Foltz, Ian N.
    Yan, Wei
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (12) : 7535 - 7562
  • [30] Engineering mammalian cell factories for improved recombinant monoclonal antibody production: Lessons from nature?
    Dinnis, DM
    James, DC
    BIOTECHNOLOGY AND BIOENGINEERING, 2005, 91 (02) : 180 - 189